Skip to main navigation Skip to search Skip to main content

Nontargeted metabolomics by high-resolution mass spectrometry to study the in vitro metabolism of a dual inverse agonist of estrogen-related receptors β and γ, dn203368

  • Sin Eun Kim
  • , Seung Bae Ji
  • , Euihyeon Kim
  • , Minseon Jeong
  • , Jina Kim
  • , Gyung Min Lee
  • , Hyung Ju Seo
  • , Subin Bae
  • , Yeojin Jeong
  • , Sangkyu Lee
  • , Sunghwan Kim
  • , Taeho Lee
  • , Sung Jin Cho
  • , Kwang Hyeon Liu
  • Kyungpook National University
  • Daegu-Gyeongbuk Medical Innovation Foundation
  • Korea Institute of Science and Technology

Research output: Contribution to journalArticlepeer-review

Abstract

DN203368 ((E)-3-[1-(4-[4-isopropylpiperazine-1-yl]phenyl) 3-methyl-2-phenylbut-1-en-1-yl] phenol) is a 4-hydroxy tamoxifen analog that is a dual inverse agonist of estrogen-related receptor β/γ (ERRβ/γ). ERRγ is an orphan nuclear receptor that plays an important role in development and homeostasis and holds potential as a novel therapeutic target in metabolic diseases such as diabetes mellitus, obesity, and cancer. ERRβ is also one of the orphan nuclear receptors critical for many biological processes, such as development. We investigated the in vitro metabolism of DN203368 by conventional and metabolomic approaches using high-resolution mass spectrometry. The compound (100 µM) was incubated with rat and human liver microsomes in the presence of NADPH. In the metabolomic approach, the m/z value and retention time information obtained from the sample and heat-inactivated control group were statistically evaluated using principal component analysis and orthogonal partial least-squares discriminant analysis. Significant features responsible for group separation were then identified using tandem mass spectra. Seven metabolites of DN203368 were identified in rat liver microsomes and the metabolic pathways include hydroxylation (M1-3), N-oxidation (M4), N-deisopropylation (M5), N,N-dealkylation (M6), and oxidation and dehydrogenation (M7). Only five metabolites (M2, M3, and M5-M7) were detected in human liver microsomes. In the conventional approach using extracted ion monitoring for values of mass increase or decrease by known metabolic reactions, only five metabolites (M1-M5) were found in rat liver microsomes, whereas three metabolites (M2, M3, and M5) were found in human liver microsomes. This study revealed that nontargeted metabolomics combined with high-resolution mass spectrometry and multivariate analysis could be a more efficient tool for drug metabolite identification than the conventional approach. These results might also be useful for understanding the pharmacokinetics and metabolism of DN203368 in animals and humans.

Original languageEnglish
Article number776
JournalPharmaceutics
Volume13
Issue number6
DOIs
StatePublished - Jun 2021
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Estrogen-related receptor γ
  • Inverse agonist
  • Liquid chromatography–tandem mass spectrometry
  • Metabolite identification
  • Metabolomics

Fingerprint

Dive into the research topics of 'Nontargeted metabolomics by high-resolution mass spectrometry to study the in vitro metabolism of a dual inverse agonist of estrogen-related receptors β and γ, dn203368'. Together they form a unique fingerprint.

Cite this